<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7156260\results\search\testTrace\results.xml">
  <result pre="review is to evaluate the efficacy of antiviral therapies in" exact="treatment" post="of COVID-19. In addition, clinical trials on the efficacy"/>
  <result pre="(MERS-CoV) have also been reviewed, in order to identify potential" exact="treatment" post="options for COVID-19. Method: An extensive search was performed"/>
  <result pre="found. The results depicted that adding Lopinavir-Ritonavir to the standard" exact="treatment" post="regimen of patients with severe COVID-19 has no benefits."/>
  <result pre="discovered so far. Recently, a Chinese research team proposed a" exact="treatment" post="protocol for management of COVID-19 patients, which included moxifloxacin,"/>
  <result pre="arbidol administration (8). However, the underlying evidence for the mentioned" exact="treatment" post="protocol is unclear, as there are no clinical trials"/>
  <result pre="used for SARS-CoV or MERS-CoV may be useful in the" exact="treatment" post="of COVID-19, due to the fact that all of"/>
  <result pre="evidence underlying the efficacy and safety of antiviral therapies in" exact="treatment" post="of COVID-19 in the current pandemic. Another goal for"/>
  <result pre="used, dose and duration of administration, route of administration and" exact="treatment" post="outcome. Any disagreements were resolved by a discussion with"/>
  <result pre="divided into two groups: lopinavir-ritonavir (99 patients) group and standard" exact="treatment" post="group. In addition to lopinavir-ritonavir (400 mg / 100"/>
  <result pre="effective than the standard treatment. Figure 1 Flow diagram of" exact="screening" post="process of present systematic review. RCT: Randomized clinical trial."/>
  <result pre="Antiviral treated patients (n) Dosage Route of administration Duration of" exact="treatment" post="Combination Main findings Randomized clinical trial Cao et al;"/>
  <result pre="4 to 11 Yes No mortality. Time from onset of" exact="treatment" post="to negative result of Cov-test was 4-11 days. Length"/>
  <result pre="2020; China (15) 24 5 to 95 8 Asymptomatic COVID-19" exact="infection" post="Not specified 21 NR NR NR Yes No mortality,"/>
  <result pre="an analysis regarding the efficacy of antiviral therapy in the" exact="treatment" post="course of COVID-19 patients. For instance, Chen et al."/>
  <result pre="drugs, whereas the group which did not receive the antiviral" exact="treatment" post="had a mortality rate of 5.6% (22). Furthermore, in"/>
  <result pre="one patient tolerated the antiviral regimen and completed the 12-day" exact="treatment" post="course. After the start of antiviral treatments, liver test"/>
  <result pre="order to find the existing evidence regarding antiviral therapies for" exact="treatment" post="of diseases caused by SARS-CoV and MERS-CoV, which are"/>
  <result pre="of lopinavir / ritonavir and interferon-Î²1b combination therapy in the" exact="treatment" post="of MERS-CoV patients. The study is currently ongoing, and"/>
  <result pre="study has examined the efficacy of antiviral therapies alone in" exact="treatment" post="of COVID-19, and all of the existing articles have"/>
  <result pre="were epidemics in recent years, impedes suggesting a potential antiviral" exact="treatment" post="for COVID-19. The current situation is a serious red"/>
  <result pre="a descriptive study The Lancet20203951022350713 12ChenQQuanBLiXGaoGZhengWZhangJet al.A report of clinical" exact="diagnosis" post="and treatment of 9 cases of coronavirus disease 2019"/>
  <result pre="study The Lancet20203951022350713 12ChenQQuanBLiXGaoGZhengWZhangJet al.A report of clinical diagnosis and" exact="treatment" post="of 9 cases of coronavirus disease 2019 Journal of"/>
  <result pre="2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine" exact="treatment" post="Bioscience trends202014164832037389 25WuJLiuJZhaoXLiuCWangWWangDet al.Clinical Characteristics of Imported Cases of"/>
  <result pre="trial Trials20202111831898511 33MomattinHAl-AliAYAl-TawfiqJAA Systematic Review of therapeutic agents for the" exact="treatment" post="of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Travel"/>
  <result pre="therapy International Journal of Infectious Diseases20131710e792e823993766 38StockmanLJBellamyRGarnerPSARS: systematic review of" exact="treatment" post="effects PLoS medicine200639e34316968120"/>
 </snippets>
</snippetsTree>
